Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Antibiotic Resistance Threats in the United States, 2013

Report
Antibiotic Resistance Threats in the United States, 2013

This report gives a first-ever snapshot of the burden and threats posed by the antibiotic-resistant germs having the most impact on human health.

Author:

Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC)

Audiences:

Policy Makers

Topic:

MDR TB

Country of Origin:

United States

View Webpage

Related Materials

Trends in Tuberculosis – United States, 2013

This report summarizes provisional TB surveillance data reported to CDC in 2013. Case counts and incidence rates continue to decline, but certain groups are disproportionately affected. TB incidence rate among foreign-born persons in 2013 was approximately 13 times greater than the rate among US born persons and the proportion of TB cases among foreign born persons increased to 64.6 percent in 2013. Also racial/ethnic disparities in TB incidence persist with TB rates among non-Hispanic Asians approximately 26 times higher than among non-Hispanic whites. Four states—California, Texas, New York, and Florida–with approximately one-third of the US population reported approximately half the TB cases in 2013. Continued progress to TB elimination in the United States will require focused TB control among populations and in geographic areas with disproportionate burden.

Report

The Urgent Threat of TB Drug Resistance

This fact sheet provides general information on TB drug resistance.

Fact Sheet

Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States

This report presents results from an expert panel convened by CDC to examine the current status of rapid drug-resistance (DR) testing in the United States; to research published evidence and current guidelines; and to provide guidance and make recommendations to CDC for developing a system to provide access to rapid drug-susceptibility testing to all TB control programs in the United States. The panel recommended that CDC establish regional laboratories to provide molecular drug-resistance testing services to state and local TB programs. A phased approach to developing and implementing the testing service was advised. The panel also strongly recommended that CDC immediately establish a service to provide molecular DR testing for TB suspects and patients at high risk of having MDR TB and those deemed high priority by the state or local TB program. The report discusses the background on tests for molecular detection of DR, general considerations and principles for a molecular DR testing service, possible scenarios and scope of testing for such a service, research needs, general recommendations, a communication plan for the report recommendations, and a list of panel members and CDC participants. The appendices include a molecular basis of DR and molecular DR tests, roles and responsibilities in a regional laboratory system for providing for molecular DR testing for TB, and a flow chart of steps in a molecular DR testing service.

Report

Global resources for the prevention,
management, and elimination of TB.